197 related articles for article (PubMed ID: 24033536)
1. Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration.
Ayoub NM; Akl MR; Sylvester PW
Cell Prolif; 2013 Oct; 46(5):538-53. PubMed ID: 24033536
[TBL] [Abstract][Full Text] [Related]
2. γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells.
Ayoub NM; Bachawal SV; Sylvester PW
Cell Prolif; 2011 Dec; 44(6):516-26. PubMed ID: 21973114
[TBL] [Abstract][Full Text] [Related]
3. γ-Tocotrienol reversal of epithelial-to-mesenchymal transition in human breast cancer cells is associated with inhibition of canonical Wnt signalling.
Ahmed RA; Alawin OA; Sylvester PW
Cell Prolif; 2016 Aug; 49(4):460-70. PubMed ID: 27323693
[TBL] [Abstract][Full Text] [Related]
4. Anti-proliferative effects of γ-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells.
Parajuli P; Tiwari RV; Sylvester PW
Cell Prolif; 2015 Aug; 48(4):421-35. PubMed ID: 26096843
[TBL] [Abstract][Full Text] [Related]
5. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity.
Shah SJ; Sylvester PW
Exp Biol Med (Maywood); 2005 Apr; 230(4):235-41. PubMed ID: 15792944
[TBL] [Abstract][Full Text] [Related]
6. γ-Tocotrienol-induced autophagy in malignant mammary cancer cells.
Tiwari RV; Parajuli P; Sylvester PW
Exp Biol Med (Maywood); 2014 Jan; 239(1):33-44. PubMed ID: 24231340
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and sesamin treatment.
Akl MR; Ayoub NM; Sylvester PW
Planta Med; 2012 Nov; 78(16):1731-9. PubMed ID: 22987298
[TBL] [Abstract][Full Text] [Related]
8. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD
Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370
[TBL] [Abstract][Full Text] [Related]
9. Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines.
Akl MR; Ayoub NM; Abuasal BS; Kaddoumi A; Sylvester PW
Fitoterapia; 2013 Jan; 84():347-59. PubMed ID: 23266736
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Shirode AB; Sylvester PW
Biomed Pharmacother; 2010 May; 64(5):327-32. PubMed ID: 19954924
[TBL] [Abstract][Full Text] [Related]
11. Intracellular signaling mechanisms mediating the antiproliferative and apoptotic effects of gamma-tocotrienol in neoplastic mammary epithelial cells.
Sylvester PW; Shah SJ; Samant GV
J Plant Physiol; 2005 Jul; 162(7):803-10. PubMed ID: 16008108
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anticancer effects of combined γ-tocotrienol and oridonin treatment is associated with the induction of autophagy.
Tiwari RV; Parajuli P; Sylvester PW
Mol Cell Biochem; 2015 Oct; 408(1-2):123-37. PubMed ID: 26112904
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
14. Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Bachawal SV; Wali VB; Sylvester PW
Anticancer Res; 2010 Feb; 30(2):429-37. PubMed ID: 20332450
[TBL] [Abstract][Full Text] [Related]
15. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
Samant GV; Sylvester PW
Cell Prolif; 2006 Dec; 39(6):563-74. PubMed ID: 17109639
[TBL] [Abstract][Full Text] [Related]
16. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Manu KA; Shanmugam MK; Ramachandran L; Li F; Fong CW; Kumar AP; Tan P; Sethi G
Clin Cancer Res; 2012 Apr; 18(8):2220-9. PubMed ID: 22351692
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
18. FGF18 Enhances Migration and the Epithelial-Mesenchymal Transition in Breast Cancer by Regulating Akt/GSK3β/Β-Catenin Signaling.
Song N; Zhong J; Hu Q; Gu T; Yang B; Zhang J; Yu J; Ma X; Chen Q; Qi J; Liu Y; Su W; Feng Z; Wang X; Wang H
Cell Physiol Biochem; 2018; 49(3):1019-1032. PubMed ID: 30196303
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells.
Wali VB; Sylvester PW
Lipids; 2007 Dec; 42(12):1113-23. PubMed ID: 17701065
[TBL] [Abstract][Full Text] [Related]
20. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
